Datopotamab deruxtecan demonstrated statistically significant PFS benefit in patients with HR+ve, HER2-low/neg breast cancer in TROPION-Breast01 Ph 3 trial
Ken Takeshita, MD, Global Head, Oncology R&D, Daiichi Sankyo, said: “The positive topline results from TROPION-Breast01 demonstrate the potential for datopotamab deruxtecan to become an important treatment option for patients with HR-positive, HER2-low or HER2-negative breast cancer in the second-line metastatic setting. We look forward to realising the full potential of this TROP2-directed antibody drug conjugate across breast cancer subtypes through our ongoing Phase III programme, including two trials in patients with triple-negative breast cancer.”
Share:
More News
“Dosing the first patient in the TNG456 Phase 1/2 trial marks a significant step for us and for patients with MTAP-deleted GBM,” said Adam Crystal, M.D., Ph.D., President, Research and Development of Tango Therapeutics. “People with GBM currently have few treatment options and a five-year survival rate below 10%. 45%
“The ASCENT-03 outcome represents the first clinically meaningful advance for this patient population in over 20 years versus chemotherapy,” said Dietmar Berger, MD, PhD, Chief Medical Officer, Gilead Sciences. “By addressing this aggressive and difficult to treat disease earlier, we can potentially improve treatment options for the high unmet need
“Early intervention in high-risk smoldering multiple myeloma demonstrated a reduction in the risk of progression or death,” said Sen Zhuang, M.D., Vice President, Oncology Clinical Research, Johnson & Johnson Innovative Medicine. “The proactive approach demonstrated in the AQUILA study is an example of Johnson & Johnson’s aspiration to get in
